Evert B. Schimmelpennink - Apr 4, 2024 Form 3 Insider Report for Contineum Therapeutics, Inc. (CTNM)

Role
Director
Signature
/s/ Peter Slover, Attorney-in-Fact
Stock symbol
CTNM
Transactions as of
Apr 4, 2024
Transactions value $
$0
Form type
3
Date filed
4/4/2024, 05:59 PM
Previous filing
Mar 25, 2024
Next filing
May 29, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CTNM Stock Option (right to buy) Apr 4, 2024 Class A Common Stock 29.4K $9.57 Direct F1
holding CTNM Stock Option (right to buy) Apr 4, 2024 Class A Common Stock 2.68K $16.18 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Options granted under the Issuer's 2012 Equity Incentive Plan (the "Plan"). The option is fully vested.
F2 Options granted under the Plan. The option shares vest and become exercisable in 24 equal monthly installments beginning on April 15, 2024, subject to the Reporting Person's continuous service.

Remarks:

Exhibit 24 - Power of Attorney